Disease · MONDO_0005344
Comparisons in its trials95
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 95
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Deaths | 238 of 6,216 | 264 of 6,162 | 12,378 | NCT00388674 | Trial comparisons |
| Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With HCC Malignant Neoplasm | 240 of 6,216 | 263 of 6,162 | 12,378 | NCT00388674 | Trial comparisons |
| Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Liver-related HBV Disease Progression | 350 of 6,216 | 375 of 6,162 | 12,378 | NCT00388674 | Trial comparisons |
| Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Non-HCC Malignant Neoplasm | 95 of 6,216 | 81 of 6,162 | 12,378 | NCT00388674 | Trial comparisons |
| Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Adjudicated Overall Malignant Neoplasms | 331 of 6,216 | 337 of 6,162 | 12,378 | NCT00388674 | Trial comparisons |
| Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): Number of Participants With Liver-related Death | 46 of 6,216 | 48 of 6,162 | 12,378 | NCT00388674 | Trial comparisons |
| Entecavir (ETV) vs Other Anti-HBV Medication (Non-ETV): serious adverse events | 56 of 6,216 | 50 of 6,162 | 12,378 | NCT00388674 | Trial comparisons |
| TMC278 vs Efavirenz: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 48 | 300 of 340 | 286 of 338 | 678 | NCT00543725 | Trial comparisons |
| TMC278 vs Efavirenz: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <400 Copies Per mL) at Week 96 | 283 of 340 | 270 of 338 | 678 | NCT00543725 | Trial comparisons |
| TMC278 vs Efavirenz: serious adverse events | 32 of 340 | 31 of 338 | 678 | NCT00543725 | Trial comparisons |
| TMC278 vs Efavirenz: Number of Participants With Virological Response (Observed, <50 Copies/mL) at Last On-Treatment Visit (Post-Week 96). | 260 of 269 | 246 of 257 | 526 | NCT00543725 | Trial comparisons |
| TDF-TDF vs ADV-TDF: deaths from any cause | 1 of 257 | 0 of 252 | 509 | NCT01300234 | Trial comparisons |
| TDF-TDF vs ADV-TDF: serious adverse events | 12 of 257 | 20 of 252 | 509 | NCT01300234 | Trial comparisons |
| ETV 0.5 mg vs ETV/TDF 0.5 mg +TDF 300 mg: serious adverse events | 13 of 182 | 14 of 197 | 379 | NCT00410072 | Trial comparisons |
| Therapeutic HBV Vaccine+Entecavir vs Placebo+Entecavir: deaths from any cause | 0 of 189 | 0 of 189 | 378 | NCT01326546 | Trial comparisons |
| Therapeutic HBV Vaccine+Entecavir vs Placebo+Entecavir: serious adverse events | 1 of 189 | 0 of 189 | 378 | NCT01326546 | Trial comparisons |
| Therapeutic HBV Vaccine+Entecavir vs Placebo+Entecavir: Percentage of Participants With HBeAg Seroconversion at Week 48 | 21 of 189 | 23 of 188 | 377 | NCT01326546 | Trial comparisons |
| Tenofovir DF vs FTC/Tenofovir DF: serious adverse events | 23 of 141 | 21 of 139 | 280 | NCT00737568 | Trial comparisons |
| Telbivudine 600 mg vs Lamivudine 100 mg: serious adverse events | 59 of 115 | 68 of 116 | 231 | NCT00076336 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Serious Adverse Events | 11 of 102 | 7 of 99 | 201 | NCT01369212 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005344/comparisons